ATRA
Atara Biotherapeutics Inc

3,382
Mkt Cap
$105.05M
Volume
63,006.00
52W High
$18.71
52W Low
$5.01
PE Ratio
6.65
ATRA Fundamentals
Price
$14.86
Prev Close
$14.57
Open
$14.61
50D MA
$13.90
Beta
2.28
Avg. Volume
53,334.35
EPS (Annual)
-$11.41
P/B
-2.87
Rev/Employee
$842,745.10
Loading...
Loading...
News
all
press releases
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six brokerages that are covering the company, MarketBeat Ratings...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Atara Biotherapeutics (NASDAQ:ATRA) CAO Sells $23,794.76 in Stock
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CAO Yanina Grant-Huerta sold 1,804 shares of the firm's stock in a transaction on Monday, November 17th. The stock was sold at an average...
MarketBeat·6d ago
News Placeholder
Atara Biotherapeutics (NASDAQ:ATRA) CEO Anhco Nguyen Sells 2,915 Shares
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) CEO Anhco Nguyen sold 2,915 shares of the company's stock in a transaction that occurred on Monday, November 17th. The shares were sold at...
MarketBeat·6d ago
News Placeholder
Atara Biotherapeutics (NASDAQ:ATRA) Issues Quarterly Earnings Results, Beats Estimates By $0.51 EPS
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) announced its quarterly earnings results on Wednesday. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts...
MarketBeat·13d ago
News Placeholder
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...
Business Wire·14d ago
News Placeholder
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.67% and -41.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
Atara Biotherapeutics (ATRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·19d ago
News Placeholder
Pacira (PCRX) Tops Q3 Earnings Estimates
Pacira (PCRX) delivered earnings and revenue surprises of +7.69% and -1.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Adma Biologics (ADMA) Q3 Earnings Match Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and +3.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·2mo ago

Latest ATRA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.